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Abstract
Chronic inflammation plays an essential role in the development of diabetic complications. Understanding the molecular
mechanisms that support inflammation is a prerequisite for the design of novel anti-inflammatory therapies. These would take
into consideration circulating levels of cytokines and damage-associated molecular patterns (DAMPs) that include the high
mobility group box 1 (HMGB1) protein which, in part, promotes the inflammatory response through TLR4 signaling. The liver,
as the source of circulating cytokines and acute-phase proteins, contributes to the control of systemic inflammation. We previ-
ously found that liver injury in streptozotocin-induced diabetic rats correlated with the level of oxidative stress, increased
expression of HMGB1, and with the activation of TLR4-mediated cell death pathways. In the present work, we examined the
effects of ethyl pyruvate (EP), an inhibitor of HMGB1 release/expression, on the modulation of activation of the HMGB1/TLR4
inflammatory cascade in diabetic liver. We observed that increased expression of inflammatory markers, TNF-α, IL-6, and
haptoglobin in diabetic liver was associated with increased HMGB1/TLR4 interaction, activation of MAPK (p38, ERK,
JNK)/NF-κB p65 and JAK1/STAT3 signaling pathways, and with decreased expression of Nrf2-regulated antioxidative en-
zymes. The reduction in HMGB1 expression as the result of EP administration reduced the pro-inflammatory activity of HMGB1
and exerted a protective effect on diabetic liver, which was observed as improved liver histology and antioxidant and inflam-
matory statuses. Our results suggest that prevention of HMGB1 release and blockage of the HMGB/TLR4 axis represents a
potentially effective therapeutic strategy aimed at ameliorating diabetes-induced inflammation and ensuing liver injury.
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Introduction
Diabetes mellitus is a metabolic disease caused by defects in
insulin secretion, insulin action, or both. It is also an inflam-
matory disease given that one of its major features is chronic
low-grade inflammation, characterized by elevated circulating
pro-inflammatory cytokines and acute-phase (AP) proteins [8,
12]. While inflammation is primarily a beneficial response
activated to restore tissue homeostasis, when the magnitude
or duration of inflammation is excessive, inflammation leads
to tissue injury. In diabetes, the presence of chronic, low-grade
inflammation increases the risk of development of insulin re-
sistance, cardiovascular complications, and kidney problems
[12]. As the major source of circulating cytokines and AP
proteins, the liver is an essential constituent of the immune
system contributing to the control of systemic inflammation
[5]. In diabetes, chronic hyperglycemia creates conditions that
promote hepatocyte injury, and inflammation can increase the
risk of development of liver disease [27]. In our previous
study, we showed that in streptozotocin (STZ)-induced dia-
betic rats, the serum levels of interleukin (IL)-6 and tumor
necrosis factor (TNF)-α are increased and that these cytokines
upregulate in the liver, in a concentration-dependent manner
haptoglobin (Hp), an AP protein with anti-inflammatory, im-
munomodulatory, and antioxidant properties [2]. We also
showed that the presence of these cytokines was strongly cor-
related with the extent of diabetes-related oxidative stress and
liver damage. Depending on its concentration, TNF-α can
either have protective or damaging effects. This has been
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demonstrated in acute liver injury [11] where its elevated pres-
ence triggers a series of intracellular events that result in the
activation of apoptosis, a type of cell death which is increased
in diabetic rat liver [33]. Since inflammation is one of the main
etiological factors in the development and progression of
diabetes-related tissue injury, it is important to investigate
diabetes-induced signaling pathways that maintain the inflam-
matory environment and to identify endogenous participants
that would be suitable therapeutic targets for controlling
inflammation.
According to Dasu and Jialal [6], high glucose level in
diabetes induces inflammation followed by cytokine release,
through increasing in Toll-like receptor (TLR) expression and
activity, and activation of nuclear factor-kappa B (NF-κB)
transcription factors. Healthy liver contains low levels of a
variety TLRs, and their expression under pathological condi-
tions is upregulated. Increased expression of TLR4 was re-
ported in liver injury models, such as partial hepatectomy
and ischemia-reperfusion, where it is involved in the clearance
of endotoxins, in the production of pro-inflammatory and anti-
inflammatory cytokines, and the generation of reactive oxida-
tive species (ROS) [14, 36]. In our previous study, we de-
scribed the involvement of TLR4 in the induction of the in-
trinsic apoptotic cell death pathway in diabetic rat liver
through interaction with exogenous high mobility group box
1 (HMGB1) protein [33].
The innate immune system can sense danger signals from
damaged hepatocytes during non-infection-related liver inju-
ry, resulting in an inflammatory response [10, 14]. HMGB1,
originally described as a chromatin-associated protein, func-
tions as a key endogenous danger signal molecule that extra-
cellularly exerts a cytokine-like effect on immune cells by
promoting pro-inflammatory signaling and release of cyto-
kines [35, 44]. HMGB1, which belongs to damage-
associated molecular pattern molecules (DAMPs), is released
passively from stressed, damaged, or dying cells and actively
from immune cells. ROS are important mediators in HMGB1
release from both immune and nonimmune cells. In studies of
hepatic ischemia-reperfusion, it was shown that this protein
mediates liver injury by acting as an endogenous activator of
TLR4 [40]. Activated TLR4 leads to activation of several
signaling pathways, including the mitogen-activated protein
kinase (MAPK), NF-κB, and Janus kinase/signal transducer
and activator of transcription (JAK/STAT) pathways that de-
termine the transcriptional activities of genes for the pro-
inflammatory cytokines IL-6 and TNF-α, and also for Hp
and other immune-related proteins [31]. Recently, Yang
et al. [46] established that Hp, or its β subunit, forms a com-
plex with HMGB1, inhibits HMGB1-mediated induction of
pro-inflammatory mediators, and elicits an anti-inflammatory
response by stimulating the production of the antioxidative
enzyme heme oxygenase-1 (HO-1) and anti-inflammatory cy-
tokines such as IL-10. Previously, we noted a significant
increase in the expression of both HMGB1 and Hp, in the
serum and liver of diabetic rats [2, 16].
The above data indicate that HMGB1 could play an impor-
tant role in mediating diabetes-related liver injury by
balancing pro- and anti-inflammatory activities through a
paracrine-like pro-inflammatory signaling mechanism. By
interacting with TLR4, exogenous HMGB1 could be involved
in a vicious cycle of enhanced cytokine production, ROS gen-
eration, and HMGB1 release that together with diabetes-
associated oxidative stress, additionally aggravate liver func-
tionality and lead to its damage. However, through the same
TLR4 signaling pathways, HMGB1 could mediate anti-
inflammatory responses by stimulating the production of
anti-inflammatory factors. Thus, it is expected that the patho-
logical role of HMGB1 in diabetic liver depends on its extra-
cellular presence. To test this hypothesis, we investigated
whether inhibition of HMGB1 secretion by the simple aliphat-
ic ester of pyruvic acid, ethyl pyruvate (EP), decreases
diabetes-related hepatocellular damage, suppresses activation
of inflammatory cascades from TLR4, and modulates the in-
flammatory status. By virtue of its ability to ameliorate multi-
ple acute inflammatory organ injuries in experimental animal
models, EP acts as an anti-inflammatory agent [45]. More
importantly, a part of its anti-inflammatory properties include
it capability to downregulate HMGB1 release [37].
Materials and methods
Animals Animal care and animal procedures were in accor-
dance with the Guide for the Care and Use of Laboratory
Animals, published by the US National Institutes of Health
(Institute for Laboratory Animal Research 1996) and ap-
proved by the Ethical Committee for the Use of Laboratory
Animals of the Insti tute for Biological Research
BSinišaStanković,^ Belgrade (No. 2-15/10). Male albino
rats of Wistar strain, weighing 200–220 g at the beginning
of the experiment, were used. The rats were housed three
per cage in a room with constant temperature and humidity
(22 ± 2 °C, 50 ± 5%, 12 h dark/light intervals) and could
freely take food and tap water.
Treatments Experimental animals were separated randomly
into the following four experimental groups: control group
(C), control group treated with EP (C + EP), diabetic group
(D), and diabetic group treated with EP (D + EP). Diabetes
was induced by a single intraperitoneal (i.p.) injection of STZ
(65 mg/kg; Sigma-Aldrich) that was dissolved in freshly pre-
pared 0.01 mol/L sodium citrate, pH 4.5. Blood glucose was
monitored using a hand-held glucometer (GlucoSure Plus,
Apex Biotechnology Corp). Blood was obtained from the
tail tip. Rats with a fasting blood glucose concentration
greater than 20 mmol/L were considered as diabetic. EP
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(Sigma-Aldrich) was freshly prepared in Ringer’s solution
(130 mM NaCl, 4 mM KCl, 2.7 mM CaCl2, pH 7.0).
According to Liang et al. [22], EP at a dose of 80 mg/kg
is effective in inhibiting HMGB1 release/secretion.
Therefore, this dose of EP was intraperitoneally adminis-
tered daily, with the first dose injected 10 days after diabe-
tes induction. EP administration continued until the end of
the study, 4 weeks after initiation of the STZ treatment,
when the rats were weighed and killed by decapitation.
Control rats were injected only with the solvent.
Tissue preparation Immediately after decapitation, the
blood was rapidly collected and the serum was obtained
by centrifugation at 2000g in an Eppendorf 5415 R centri-
fuge (Sigma-Aldrich) for 15 min. The liver was removed
and weighed and a liver section was processed for micro-
scopic examination. For measuring the activities of antiox-
idative enzymes in the liver, a 10% homogenate of fresh
liver (500 mg) was prepared in sucrose buffer (250 mM
sucrose, 1 mM EDTA, 50 mM Tris-HCl, pH 7.4). The
homogenate was centrifuged at 100,000g for 90 min at
4 °C and the resulting supernatant was aliquoted and stored
at − 80 °C. The rest of the liver was snap-frozen in liquid
nitrogen and kept at − 80 °C.
Preparation of the whole liver homogenate and subcellular
fractions For whole liver homogenate preparation, frozen rat
liver tissue (200–400 mg) was homogenized at 4 °C in a
Dounce tissue grinder in ice-cold homogenization buffer
(250 mM sucrose, 10 mM Tris pH 7.6, 1 mM EDTA) supple-
mented with phosphatase inhibitor Mix I and protease inhib-
itorMix G (Serva). The homogenate was centrifuged at 9700g
for 20 min at 4 °C, and the resulting supernatant was
aliquoted, snap-frozen in liquid nitrogen, and stored at −
80 °C. For preparation of the cytosolic and nuclear protein
extracts, the commercial Subcellular Protein Fractionation
Kit for Tissues (Cat. no 87790, Pierce) was used. Liver tissue
(200 mg) was homogenized in 10 volumes of ice-cold cyto-
plasmic extraction buffer containing protease inhibitor Mix G
(Serva) and the homogenate was centrifuged at 500g for 5 min
at 4 °C. The resulting supernatant (cytoplasmic extract) was
cleared by centrifugation, divided into aliquots, and stored at
− 80 °C. The 500g pellet was resuspended in ice-cold mem-
brane extraction buffer containing protease inhibitors,
vortexed on the highest setting, incubated at 4 °C for 10 min
with gentle mixing, and centrifuged at 3000g for 5 min. The
resulting pellet was resuspended in ice-cold nuclear extraction
buffer supplemented with protease inhibitor Mix G, vortexed
on the highest setting for 15 s, incubated at 4 °C for 30 min,
and centrifuged at 5000g for 5 min at 4 °C. The resulting
supernatant (nuclear extract) was separated into aliquots and
stored at − 80 °C. Protein concentrationwas determined by the
method of Lowry.
Determination of serum glucose, insulin, and alanine amino-
transferase concentrations Serum glucose was measured by
the glucose oxidase procedure using a glucose GOD/PAP test
kit (Randox Laboratories, detection limit 0.4–41 mmol/L on
Shimadzu UV-160 spectrophotometer). Serum insulin was
measured by the rat insulin ELISA kit purchased from
Mercodia AB (Uppsala). Serum alanine aminotransferase
(ALT) was measured with an ILab-600 Analyzer
(International Laboratory).
Immunohistochemistry Liver samples were fixed in Bouin’s
solution and embedded in paraffin. For examination of
diabetes-related hepatocyte deterioration, 5-μm-thick sections
of rat liver were deparaffinized, rehydrated, stained with
hematoxylin/eosin (H&E), and examined using standard light
microscopy (Opton, Zeiss). Representative liver sections were
stained by the immunohistochemical method. After
deparaffinization and rehydration of sections, endogenous
peroxidase activity was blocked by incubation in methanol
containing 0.3% H2O2 for 15 min at room temperature.
Heat-induced antigen retrieval was performed using 0.1 mol/
L sodium citrate buffer pH 6.0 and then heated at 750 W in a
microwave oven three times for 7 min. Non-specific back-
ground staining was reduced by incubation with normal por-
cine serum (Dakopatts) diluted 1:10 v/v in PBS for 45 min.
The sections were incubated with polyclonal rabbit anti-
HMGB1 antibody in PBS (1:500 v/v; ab18256, Abcam) over-
night at 4 °C, followed by washing in PBS, three times for
5 min. For the negative control, liver sections were incubated
in PBS without primary antibody. The secondary antibody,
polyclonal bovine anti-rabbit IgG (1:100 v/v in PBS; sc
2379, Santa Cruz Biotechnology) was applied and incubated
for another 60 min and rinsed in PBS for 10 min. Antibody
localization was visualized by a 3,3-diaminobenzidine tetra-
chloride (DAB) liquid substrate chromogen system (Serva).
The sections were thoroughly washed in distilled water, coun-
terstained with hematoxylin, and mounted on DPX (Sigma-
Aldrich). All light microscopy images of the liver sections
were made using a DM RB Photomicroscope (Leica) with a
DFC 320 CCD Camera (Leica) for the image acquisition.
Antioxidant enzyme assays To measure the activities of anti-
oxidative enzymes in the liver, a 10% homogenate of fresh
liver, prepared in sucrose buffer, was used. Total activity of
superoxide dismutase (SOD) was determined by the epineph-
rine method [30] which is based on the measurement of inhi-
bition of epinephrine auto-oxidation by the SOD contained in
the sample at 480 nm. The reaction was performed in a reac-
tion medium containing 3 mM epinephrine dissolved in 0.1 N
HCl and 50 mM Na2CO3 with 1 mM EDTA, pH 10.2. SOD
activity was expressed as SOD units per milligram of protein.
One unit is defined as the amount of enzyme that inhibits the
rate of epinephrine auto-oxidation by 50%. Catalase (CAT)
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activity was measured by the method of Beutler [4]. The re-
action is based on the rate of H2O2 degradation by CAT
contained in the analyzed samples. The reaction was per-
formed in an incubation mixture containing 50 μl buffer
(1 M Tris HCl pH 8.0, 5 mM EDTA), 5–10 μl sample, and
1 ml 10 mM H2O2 liver homogenate, and 10 mM H2O2 (A =
0.800–0.860). The rate of decrease in absorbance was mea-
sured at 230 nm. CATactivity was expressed asmicromoles of
H2O2 per minute per milligram of protein (U/mg of protein) in
liver homogenates, with one CAT activity unit defined as
1 μmol of H2O2.
Western immunoblotting Protein samples of serum (1 μl),
whole liver homogenates (30 μg), cytosolic (30 μg), or nucle-
ar (25 μg) extracts were separated by 12% SDS-PAGE, trans-
ferred onto polyvinylidene difluoride (PVDF) membrane
(Hybond-P, Amersham Pharmacia Biotech), which was
blocked in a solution of 0.2% Tween 20, 50 mM Tris–HCl
pH 7.6, 150mMNaCl containing 5% non-fat condensedmilk.
After protein transfer, the PVDF membrane was incubated
with a primary antibody for 1.5 h at room temperature. The
following primary antibodies were used for the Western blot-
ting: Abcam—rabbit polyclonal antibodies for CAT (ab1877),
Hp (ab131236), HMGB1 (ab18256), Nrf2 (ab 31163), NF-κB
p65 (Ab 7970), TLR4 (Ab 83444), β-actin (Ab 8227), mouse
monoclonal antibody for TNF-α (ab1793); Santa Cruz
Biotechnology—rabbit polyclonal antibodies for MnSOD/
SOD-2 (sc 30080), p38 (sc 535), ERK1(sc-94), p-p38 (sc
7975-R), p-NF-κB p65 (sc 33039), mouse monoclonal for
JNK (sc 1648), goat polyclonal antibodies for IL-6 (sc
1266), p-ERK (sc 16982), p-JNK (sc 12882), p-JAK1 (sc
16773), CuZnSOD/SOD-1 (sc8637), HO-1 (sc 1796),
Lamin B (sc6217); Cell Signaling Technology—rabbit poly-
clonal antibody for p-STAT3-ser (9134S). The blots were
probed with horseradish peroxidase-conjugated secondary an-
tibody purchased from Santa Cruz Biotechnology—bovine
anti-rabbit IgG (sc 2379), bovine anti-goat IgG (sc 2378);
Abcam—goat anti-rabbit IgG (ab 97051); Cell Signaling—
anti-mouse IgG (7076S). For reprobing, the membranes were
incubated in 2% SDS, 100 mM β-mercaptoethanol, and
62.5mMTris–HCl pH 6.8 for 35min at 50 °C, and then rinsed
three times, blocked, and probed again with another antibody.
Immunoreactive bands were identified by an enhanced chemi-
luminescence (ECL) detection system (Santa Cruz
Biotechnology). The results were analyzed using
TotalLabPhoretix electrophoresis software (ver. 1.10).
Immunoprecipitation Immunoprecipitation was performed as
previously described [33]. The whole liver homogenate
(500 μg) was precleared by incubation with control IgG and
protein A/G agarose (Santa Cruz Biotechnology) and the
precleared supernatant was incubated overnight at 4 °C
with 2 μg of anti-HMGB1 antibody (ab18256) in TEG
buffer (10 mM TrisHCl, pH 7.6, 4 mM EDTA, 10% glyc-
erol, 50 mM NaCl). A/G-agarose-coupled beads were
added and incubated on a shaker for an additional 30 min
at 4 °C. The beads were pelleted by centrifugation (9300g,
1 min, 4 °C.) and washed five times in TEG buffer. The
immunoprecipitated proteins were eluted from the beads
by heating in sample buffer at 95 °C for 10 min and sepa-
rated by 12% SDS-PAGE. The obtained immunoprecipi-
tate was analyzed by Western immunobloting. For back-
ground elimination of heavy and light chains during immu-
noprecipitation, Clean-Blot™ IP Detection Reagent (HRP)
was used according to the manufacturer’s instructions
(21230, Thermo Fisher Scientific).
Statistical analysisAll experiments were repeated at least three
times. The data presented as the means ± SE. For intergroup
comparison between twomeans, one-way analysis of variance
(ANOVA) followed by theMann-WhitneyU test was applied.
Values of P < 0.05 were considered statistically significant.
Results
Effects of EP on the diabetic status and liver injury
Four weeks after completion of the STZ treatment, the rats
developed diabetes. The animals exhibited a 30% decrease
in body weight (P < 0.05), a sixfold increase (P < 0.05) in
serum glucose concentration, and a threefold decrease (P <
0.05) in serum insulin concentration (Table 1, n = 15). A dis-
turbance in liver functioning was manifested as a 2.3-fold
(P < 0.05) increase in serum ALT activity (Table 1, n = 15).
Histological examination of the livers of diabetic rats (Fig. 1,
n = 9) revealed loss of the usual concentric arrangement of
hepatocytes and the presence of hydropic degeneration of he-
patocytes, hepatocellular necrosis, reduction in glycogen con-
tent, and prominent Kupffer cells. Diabetic rats treated with
EP (80 mg/kg, 18 days, n = 15) displayed less weight loss
(P < 0.05) and improved liver injury, manifested by a 35%
decrease (P < 0.05) in serum ALT activity in comparison to
diabetic rats (Table 1, n = 15). In addition, liver architec-
ture was normalized, the cytoplasm was homogeneous,
exhibiting minimal vacuolization, and the number of dete-
riorated and necrotic cells was strongly reduced (Fig. 1,
n = 9). Kupffer cells were less prominent. In EP-treated
diabetic rats, the serum glucose concentration was not sig-
nificantly changed and while insulin concentration was in-
creased 1.6-fold (P < 0.05, n = 15) in comparison to dia-
betic rats, it remained decreased (by 47%; P < 0.05) in
comparison to control animals. The EP treatment of control
rats did not elicit significant changes in the examined bio-
chemical and histological parameters.
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Antioxidative and anti-inflammatory effect of EP
on the liver of diabetic rats
As EP posseses antioxidative and anti-inflammatory activities
[37], we examined whether it changed the antioxidative and
inflammatory responses in the liver of STZ-induced diabetic
rats. The activities of CAT and total SOD were decreased by
about 24 and 22%, respectively (Fig. 2a, P < 0.05, n = 15) in
diabetic liver. In the diabetic group treated with EP, the activ-
ities of both CAT and SOD were increased 1.2- and 1.4-folds,
respectively P < 0.05, n = 15) when compared to diabetic rats
(Fig. 2a). Thus, EP restored the activity of SOD to the control
level while the activity of CAT remained about 11% (P < 0.05)
below the control level.
Relative changes in CuZnSOD and MnSOD levels were
also examined. Western immunoblot analysis of whole liv-
er homogenates of diabetic rats (Fig. 2b, n = 15) showed a
nearly twofold decrease (P < 0.05) in CAT protein expres-
sion and a twofold increase (P < 0.05) in MnSOD protein
expression, while the level of CuZnSOD protein was un-
changed when compared to the control group. Compared to
untreated diabetic rats, the EP-treated diabetic rats
displayed a 1.5-fold (P < 0.05) increase in liver CAT pro-
tein expression and a 30% (P < 0.05) decrease in liver
MnSOD protein expression. No differences were observed
between control rats and EP-treated control rats, as the
treatment of control rats with EP did not elicit significant
changes in activities nor in relative protein levels of the
examined antioxidative enzymes.
Since the inflammation in STZ-induced diabetic rats is
characterized by increased levels of pro-inflammatory cy-
tokines and elevated hepatic production of Hp [2], we ex-
amined the effects of EP on the changes in the relative
expression levels of TNF-α, IL-6, and Hp. Western analy-
sis of whole liver homogenates showed that in diabetic
rats, the levels of TNF-α and IL-6 were increased 6.7-
and 3.3-folds, respectively (Fig. 3, P < 0.05, n = 15) as
compared to control rats. EP treatment of diabetic rats led
to three and twofold decreases in TNF-α and IL-6, respec-
tively, when compared to the diabetic group (Fig. 3, P <
0.05, n = 15). However, their expression remained in-
creased 2.3- and 1.7-folds, respectively (P < 0.05), when
compared to control rats. The changes in TNF-α and IL-6
levels were accompanied by changes in hepatic production
Fig. 1 EP ameliorates
histopathological changes in the
liver of diabetic rats.
Photomicrographs of liver
specimens showing normal
architecture and cell structure in
control rats (C) and control rats
treated with EP (C + EP). In
diabetic rats (D),
photomicrographs show damaged
architecture, prominent Kupffer
cells, significant hydropic
degeneration, and necrosis of
hepatocytes. The diabetic group
treated with EP (D + EP) exhibits
almost normal architecture,
minimal presence of necrosis and
hepatocyte degeneration, and less
prominent Kupffer cells. H&E
stain, ×400
Table 1 The effects of EP on
body weight and serum
concentration of glucose, insulin,
and ALT in diabetic rats
C D C + EP D + EP
Body weight (g) 315.5 ± 12.5a 222 ± 9.9b 278 ± 13.2a 268 ± 11.8c
Glucose (mmol/l) 6.3 ± 0.3a 37.3 ± 3.2b 8.6 ± 0.6a 35.6 ± 3.1b
Insulin (mIU/l) 61.5 ± 7.2a 20.9 ± 2.4b 50.8 ± 5.4a 32.7 ± 3.6c
ALT (U/I) 66.7 ± 7.4a 151.9 ± 10.1b 58.4 ± 5.3a 98.7 ± 8.8c
C control rats,D diabetic rats,C+ EP control rats treated with EP,D+EP diabetic rats treated with EP. Values are
means ± SE from three independent experiments performed in triplicate, n = 15. a,b,cMean values within a row
with unlike superscript letters were significantly different (P < 0.05)
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of Hp. According to Western analysis of whole liver ho-
mogenates, treatment of diabetic rats with EP led to a 33%
decrease in elevated Hp-β, which remained 1.3-fold higher
than in the control group (Fig. 3, P < 0.05, n = 15). Again,
no differences were observed between control rats and EP-
treated control rats, as control rats that were treated with
EP did not exhibit any significant changes in protein levels
of the examined inflammatory markers.
Effect of EP on HMGB1 expression in diabetic rat
serum and liver
According to numerous studies, EP inhibits HMGB1
secretion/release mostly at the level of nuclear-to-
cytoplasmic translocation [37], suggesting that this contrib-
utes to its anti-inflammatory effect. To determine whether
EP inhibits diabetes-induced subcellular translocation of
Fig. 2 Antioxidative status in diabetic rat liver after treatment with EP. (a)
The activities of antioxidative enzymes, catalase (CAT), and total
superoxide-dismutase (SOD) were determined spectrophotometrically.
(b) Protein expression levels of CAT, copper-zinc superoxide-dismutase
(CuZnSOD), and manganese superoxide-dismutase (MnSOD) in whole
liver homogenates (WH) were determined by Western immunoblotting.
β-actin was used as a loading control. C control rats, D diabetic rats, C +
EP control rats treated with EP, D + EP diabetic rats treated with EP.
Immunoblots obtained from at least three independent experiments were
quantified by densitometric analysis and are presented in the graphs. The
values in the graphs are means ± SE, n = 15. a,b,cMean values with unlike
letters were significantly different (P < 0.05)
Fig. 3 EP reduces diabetes-induced expression of inflammatory markers
TNF-α, IL-6, and haptoglobin (Hp). The protein expression levels of
TNF-α, IL-6, and Hp in whole liver homogenates (WH) were determined
by Western immunoblotting. β-actin was used as a loading control. C
control rats, D diabetic rats, C + EP control rats treated with EP, D + EP
diabetic rats treated with EP. Immunoblots obtained from at least three
independent experiments were quantified by densitometric analysis and
are presented in the graphs. The values in the graphs are means ± SE, n =
15. a,b,cMean values with unlike letters were significantly different (P <
0.05)
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HMGB1, liver tissue sections were first analyzed by immuno-
staining. Liver sections of diabetic rats (Fig. 4a, n = 9) showed
HMGB1 staining inside the cytoplasm, in contrast to control
sections, where intra-nuclear HMGB1 staining was promi-
nent. In contrast to diabetic rats, in the EP-treated diabetic
group, aside from a faint cytoplasmic staining, HMGB1-
positive staining was mostly intra-nuclear (Fig. 4a, n = 9).
These changes were confirmed by Western analysis of
HMGB1 expression in cytosolic and nuclear extracts, and
in whole liver homogenates and serum (Fig. 4b, n = 15). In
the liver of diabetic rats, the relative level of nuclear
HMGB1 decreased 5.5-fold (P < 0.05) and increased 2.4-
fold (P < 0.05) in the cytosolic extracts. These changes
were accompanied by a 2.4-fold (P < 0.05) increase in
HMGB1 expression in the whole liver homogenate and a
2.2-fold increase in the serum (P < 0.05). The EP treatment
prevented the extracellular release of HMGB1, which is
supported by the 1.7- and 1.2-fold (P < 0.05) increases in
relative HMGB1 levels in both nuclear and cytoplasmic
extracts, respectively, and its reduced expression in the
liver homogenate and serum by about 41 and 31%, respec-
tively (P < 0.05) when compared to the diabetic group. The
EP treatment of control rats did not affect subcellular trans-
location of HMGB1.
Fig. 4 EP reduces HMGB1 expression and its cytoplasmic translocation
in diabetic liver. (a) Immunohistochemistry staining showing that in the
control (C) and control group treated with EP (C + EP), HMGB1 was
distributed mostly in the cell nucleus (indicated with arrowheads).
Cytoplasmic translocation of HMGB1 was observed in the diabetic (D)
group (indicated with arrows). EP treatment of diabetic rats (D + EP)
significantly decreased cytoplasmic translocation of HMGB1. ×400. (b)
HMGB1 protein expression levels in the liver nuclear extract (NE),
cytosolic extract (CE), whole homogenate (WH), and serum were
assessed by Western immunoblotting . β-actin and lamin B were used
as a loading controls. Immunoblots obtained from at least three indepen-
dent experiments were quantified by densitometric analysis and are pre-
sented in the graphs. The values in the graphs are means ± SE, n = 15.
a,b,cMean values with unlike letters were significantly different (P < 0.05)
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Effect of EP on the interaction of HMGB1 with TLR4
in diabetic rat livers
Since extracellular HMGB1 initiates inflammatory pathways
through interaction with TLR4, we next performed co-
immunoprecipitation analysis. Immunoprecipitation of
HMGB1 from whole liver homogenates, followed by
Western immunoblot analysis with TLR4 antibody, revealed
a 1.7-fold increase (Fig. 5, P < 0.05, n = 9) in interaction be-
tween these two proteins in diabetes, as compared to the con-
trol. The interaction of HMGB1 and TLR4 decreased to the
control level after the treatment with EP (Fig. 5, P < 0.05).
HMGB1/TLR4-mediated activation of MAPK signaling
pathways in diabetic liver
MAPKs (p38, JNK, ERK1/2) and NF-κB p65 play pivotal
roles in intracellular TLR4 signaling events. NF-κB p65 has
been shown to be involved in the regulation of expression of
genes that encode inflammatory cytokines TNF-α and IL-6,
as well as Hp and the antioxidative enzymes CuZn- and
MnSOD [31]. We therefore, investigated whether changes in
the level of interaction between HMGB1 and TLR4 influence
p38, JNK, ERK, and NF-κB p65 activation in the liver of
diabetic rats. Western immunoblot analysis of the cytosol ex-
tracts did not reveal any changes in the total expression of
these proteins in the liver of diabetic rats, irrespective of
whether they were or were not treated with EP (Fig. 6a, n =
15). However, phosphorylation activates all three types of
MAPKs. Western immunoblot analysis with antibodies
against phosphorylated forms of p38, JNK, and ERK revealed
that the increased level of interaction between HMGB1 and
TLR4 was accompanied by 2- and 1.9-fold increases in acti-
vation of p38 and 46 kDa JNK in diabetic rat liver, respective-
ly (Fig. 6a, P < 0.05, n = 15), as compared to the control.
Increased phosphorylation of 42 kDa and 44 kDa ERK iso-
forms (about 2.4-fold and 1.7-folds, respectively, P < 0.05)
was also detected. A decrease in the level of interaction be-
tween HMGB1 and TLR4 after the treatment with EP led to
decreased activation of p38, 46 kDa JNK, and both 42 kDa
and 44 kDa isoforms of ERK (1.7-, 1.3-, 1.2-, and 1.3-folds,
respectively, P < 0.05), as compared to diabetic rats. However,
the presence of activated MAPKs remained higher (P < 0.05)
than in the control group (P < 0.05). Western analysis showed
an increased nuclear presence of phosphorylated NF-κB p65
(1.6-fold, P < 0.05, n = 15) in diabetic rat liver. While the
treatment with EP reduces its nuclear presence by about
30% (P < 0.05), compared to the diabetic group, it remained
24% (P < 0.05) above the control level. The EP treatment of
control rats did not elicit significant changes in the levels of
the examined MAPKs and NF-κB p65.
HMGB1/TLR4-mediated activation of JAK1/STAT3
signaling in diabetic liver
STAT3 is one of the main transcription factors involved in the
upregulation of Hp gene transcription [41]. Studies have re-
vealed a correlation between the HMGB1-induced macro-
phage release of TNF-α and IL-6 and the activation of the
JAK/STAT signaling pathway [23] and crosstalk between
JAK1/STAT3 signaling and TLR4 [42, 48]. Thus, we next
investigated whether changes in the level of interaction be-
tween HMGB1 and TLR4 influence the activation of the
JAK1/STAT3 signaling pathway in diabetic liver. Western
analysis of the cytosol extract from the liver of diabetic rats
showed that the increased level of HMGB1 and TLR4 inter-
action (Fig. 5) was associated with a 3.3-fold increase (Fig. 6b,
P < 0.05, n = 15) in JAK1 activation by phosphorylation.
JAK1 activation was accompanied by the increased presence
of phosphorylated STAT3 isoforms on serine residues (3.3-
fold for STAT3 p91 and 2.0-fold for STAT3 p86, P < 0.05,
n = 15) in the nuclear extracts. The decrease in interaction
betweenHMGB1 and TLR4 in the liver of diabetic rats treated
with EP was accompanied by a 20% (P < 0.05) decrease in
JAK1 phosphorylation and by significant decreases in phos-
phorylation of both 91 kDa and 86 kDa STAT3 (25 and 32%,
respectively, P < 0.05, n = 15), levels that were 2.4-fold higher
Fig. 5 EP reducesHMGB1 interactions with TLR4 in the liver of diabetic
rats. Western immunoblotting of immunoprecipitated HMGB1 (IP
HMGB1) from whole liver homogenates, with anti-TLR4 antibody. C
control rats, D diabetic rats, C + EP control rats treated with EP, D +
EP diabetic rats treated with EP. Immunoblots were quantified by densi-
tometric analysis and are presented in the graphs. The values in the graphs
are means ± SE, n = 9. a,bMean values with unlike letters were signifi-
cantly different (P < 0.05)
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for STAT3 p91 and 1.4-fold higher for STAT3 p86 when com-
pared to the control (P < 0.05).
HMGB1/TLR4 interactions, Nrf2 signaling,
and HO-1expression in diabetic liver
Persistent oxidative stress, which contributes to the progress
of inflammatory response in diabetes, is the consequence of
downregulation antioxidative enzyme genes and their de-
creased enzymatic activities. Nrf2 is a transcription factor that
regulates the transcription of antioxidant genes, such as CAT
and HO-1, and is an established inhibitor of NF-κB p65 ac-
tivity [24]. Several lines of evidence indicate that induced
expression of HO-1 attenuates cellular damage and inflamma-
tion [1] and that HO-1 negatively regulates HMGB1 in in-
flammatory conditions [32]. To examine whether diabetes-
related increased expression of HMGB1 downregulates the
cytoprotective response through induction of an inflammatory
pathway (NF-κB p65), we analyzed the expression of Nrf2 in
liver cytosol and nuclear extracts of diabetic rats, the Nrf2 to
NF-κB p65 ratio, and HO-1 expression in the cytosol. Using
Western blot analysis (Fig. 7), we observed that the level of
Nrf2 in the cytosol fraction prepared from diabetic rats was
increased 1.25-fold (P < 0.05, n = 15) when compared to the
control group, while nuclear expression was decreased by
20% (P < 0.05, n = 15). Considering that NF-κB p65 nega-
tively regulates Nrf2 signaling, we determined the ratio be-
tween Nrf2 and NF-κB p65 (Fig. 7). This ratio was not sig-
nificantly changed in the cytosol fraction of diabetic liver de-
spite the increase in the relative cytosol level of NF-κB p65
(1.4-fold, P < 0.05). In diabetic liver, nuclear expression of
total NF-κB p65 increased 1.23-fold (P < 0.05, n = 15),
Fig. 6 EP reduces HMGB1/TLR4-induced activation of downstream (a)
MAPKs/NF-κB p65 and (b) JAK1/STAT3 inflammatory pathways in
diabetic liver. Protein expression levels of total and phosphorylated
MAPKs (p38, ERK, JNK) and phosphorylated JAK1 in the cytosolic
extracts (CEs) of rat liver and phosphorylated NF-kB p65 and STAT3
in the nuclear extracts (NE) were assessed by Western immunoblotting.
β-actin and lamin B were used as a loading controls. C control rats, D
diabetic rats, C + EP control rats treated with EP, D + EP diabetic rats
treated with EP. Immunoblots obtained from at least three independent
experiments were quantified by densitometric analysis (summarized in
the graphs). The graph (a, upper) shows the results of quantification of the
p-p38/p38, p-ERK/ERK, p-JNK p46/JNK p46 ratios determined at the
protein level. The values in the graphs are means ± SE, n = 15. a,b,cMean
values with unlike letters are significantly different (P < 0.05)
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resulting in a decrease in the Nrf2 to NF-κB p65 ratio by 34%
(P < 0.05), when compared to the control. The expression of
HO-1 in the cytosol from diabetic liver was not significantly
different when compared to the control. Treatment of control
rats with EP did not elicit significant changes in the cytosol
and nuclear Nrf2/NF-κB p65 ratios, while the expression of
HO-1 in the cytosol was increased 1.3-fold (P < 0.05, n = 15).
In the liver of diabetic rats treated with EP, the relative level of
Nrf2 was decreased by 29% (P < 0.05, n = 15) in the cytosol,
when compared to the diabetic group, while its nuclear ex-
pression was increased by 50% (P < 0.05, n = 15) when com-
pared to the diabetic group and 20% (P < 0.05), relative to the
control. Accordingly, the Nrf2/NF-κB p65 ratio was de-
creased by 23% (P < 0.05) in the cytosol and increased 1.7-
fold (P < 0.05) in the nuclear fraction, when compared to the
diabetic group. The expression of HO-1 in the cytosol from
the liver of diabetic rats treated with EP was increased 1.4-fold
(P < 0.05, n = 15), when compared to the diabetic group.
Discussion
Adjustment of the inflammatory processes in diabetes is a
matter of great interest in basic and clinical research, given
that inflammatory pathways assume pivotal roles in the devel-
opment and progression of many diabetic complications. The
presented results highlight the contribution of HMGB1 pro-
tein in the development/progression of liver injury in experi-
mentally induced diabetes because of its pro-inflammatory
activities. In diabetic liver, HMGB1 is secreted from necrotic
or damaged cells and immunologically activated innate im-
mune cells [35]. Recently, we showed that diabetes
upregulates HMGB1 expression [16] and that the increased
expression of HMGB1 and the prevailing HMGB1/TLR4 sig-
naling promote liver cell death, contributing to liver damage
[33]. The results presented in this study further show that
HMGB1 significantly furthered the inflammatory state in di-
abetic liver as a result of the HMGB1/TLR4-mediated in-
crease in production of inflammatory markers TNFα, IL-6,
and Hp. Increased interaction between HMGB1 and TLR4
leads to the activation of MAPK and JAK1 signaling cascades
and subsequent to activation and nuclear translocation of
NF-κB p65 and STAT3, the key transcriptional activators of
the genes for TNF-α, IL-6, and Hp. TNF-α and IL-6 which
are secreted after HMGB1 stimulation by promoting further
HMGB1 release from liver cells amplify the inflammatory
response in a positive feedback loop [28]. Additionally, we
observed that activation of the HMGB1/TLR4 axis leads to
decreased nuclear expression of Nrf2 and consequently Nrf2-
related expression of antioxidative enzymes, such as CAT,
thereby augmenting the oxidative stress. The ROS, by induc-
ing the release of HMGB1, can also amplify inflammatory
Fig. 7 EP reduces the HMGB1/TLR4-mediated decrease in Nrf2-
antioxidant signaling in diabetic liver. Protein expression levels of HO-
1 in the cytosolic fraction (CE) and Nrf-2 and NF-κB p65 in the cytosolic
and nuclear fraction (NE) were assessed byWestern immunoblotting and
quantified by densitometric analysis. The upper graph shows the
quantification of HO-1 protein levels. The lower graph shows the results
of quantification of the Nrf2/NF-κB p65 ratios. C control rats, D diabetic
rats,C+ EP control rats treated with EP,D+ EP diabetic rats treated with
EP. The values in the graphs are means ± SE, n = 15. a,b,cMean values
with unlike letters are significantly different (P < 0.05)
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responses and liver damage. Although expression of HO-1 is
predominantly Nrf2-regulated, it can be augmented in differ-
ent cells and conditions by other mechanisms of transcription-
al activation. In accordance with Liu et al. [25] who showed
that HO-1 transcription can be positively regulated by activat-
ed STAT3, we propose that sustained HO-1 expression in
diabetic liver was the consequence of STAT3 activity.
Evankovich et al. [13] reported that the release of HMGB1
can be induced by TLR4 itself, since in ischemic liver tissue,
TLR4-dependent ROS production was shown to be responsi-
ble for the release of HMGB1 into the extracellular milieu.
The reduction in HMGB1 expression in the serum and liver of
diabetic rats after chronic administration of EP reduced the
cytokine activity of HMGB1 and had a protective effect on
diabetic liver which was observed as improvements in liver
histology and the antioxidant and inflammatory status. These
results suggest that the extent of liver damage in diabetes
depends on the expression level of HMGB1 and its pro-
inflammatory activities, indicating that inhibition of
HMGB1 secretion could be considered as a prime target for
alleviating liver damage in diabetes.
Accumulating evidences indicate that EP is a multi-
functional protective agent capable to mitigating tissue dam-
age caused by various stressors [21]. The mechanisms under-
lying its anti-inflammatory and antioxidative effects are dif-
ferent and include suppression of the HMGB1 release [37],
suppression of pro-inflammatory cytokine production via in-
hibition of ROS-dependent STAT signaling [18] or DNA-
binding of NF-κB p65 [17], and induction of Nrf2 translo-
cation from the cytosol to the nucleus and subsequent up-
regulation of HO-1 [19]. The results from this study show
that all of the proposed mechanisms were associated with
the observed protective effects of EP on diabetic rat liver.
They also suggest that prevention of HMGB1 release is the
primary event through which EP decreases STAT3 and
NF-κB p65 activity and increases nuclear expression of
Nrf2 and liver expression of HO-1.
The inflammatory process is complex since it is regulated
by the intricate interplay between cytokines and factors with
pro- and anti-inflammatory effects. HMGB1, as a cytokine-
like protein, is capable of inducing the production of multiple
pro-inflammatory mediators by a variety of cells and, simul-
taneously, it probably induces its own release from activated
monocytes and macrophages. This implicates HMGB1 as the
central player in pro-inflammatory reactions. However, some
of the pro-inflammatory mediators produced in response to
HMGB1, such as IL-6, produce anti-inflammatory effects thus
revealing the dual role of HMGB1 as a pro- and anti-
inflammatory molecule. Hp is a major AP protein principally
produced in liver by hepatocytes, whose concentration in the
circulation increases after establishment of the inflammatory
reaction, and is generally viewed as an anti-inflammatory
component [5]. Hp gene is primarily induced by IL-6 type
cytokines whose receptors mediate the activation of transcrip-
tion factor STAT3 and CCAAT/enhancer binding proteinβ [5,
41]. In the present study, we show that the increased expres-
sion of HMGB1 in diabetic liver was accompanied by in-
creased production of Hp. Decreased HMGB1 release caused
by EP administration attenuated Hp expression. The observed
change in Hp expression correlated with the changes in the
level of HMGB1/TLR4 interactions, the activation of down-
stream MAPK and JAK kinases, and with the activation of
NF-κB p65 and STAT3 transcription factors. Recently, it was
reported that secreted Hp, or its β subunit, acts as an active
HMGB1 antagonist capable of binding and inhibiting the pro-
inflammatory properties of HMGB1 that are mediated through
the TLR4 signaling pathway [46]. Hp can bind to the fully
reduced and disulfide form of HMGB1 which is generated in
oxidative stress and is involved in cytokine production. This
suggests that HMGB1, by stimulating Hp synthesis and secre-
tion in diabetes, could form a negative feedback loop and
thereby lower its own pro-inflammatory activities. However,
the results from our study suggest that inhibition of HMGB1
activities with Hp was probably ineffective in diabetes. A
possible explanation could be that glycation of Hp, which is
markedly accelerated in diabetes, impaired protein binding
and functions. Spiller et al. [38] reported that Hp in the blood-
stream of diabetic patients underwent glycation on lysine-141.
Also, Asleh et al. [3] established that in diabetic patients,
glycated hemoglobin abrogated the Hp protection function
against hemoglobin-driven oxidative injury.
Activated STAT3 also possesses pro-inflammatory and
anti-inflammatory activities and is primarily activated by the
IL-6-type receptor-stimulated JAK/STAT pathway.
Phosphorylation of both JAK1 and JAK 2 is necessary for
STAT3 phosphorylation on tyrosine residues, its dimerization,
and translocation to the nucleus [42]. Activation of STAT3
from TLR4 has also been described [47]. Activated TLR4
could trigger the activation of ERK, JNK, and p38 MAPKs
that phosphorylate STAT3 on serine 727 residues, which is
required for maximum transactivation capacity of STAT3
[7]. In the present study, we observed that the HMGB1-
mediated activation of TLR4 in diabetic liver was accompa-
nied by increased activation of JAK 1 and STAT3 phosphor-
ylation on serine residues. The activation of STAT3 by phos-
phorylation is essential for a normal inflammatory response;
however, prolonged activation of STAT3 could contribute to
chronic inflammation by supporting the sustained expression
of a subset of proteins with roles in inflammation, including
the STAT3 gene itself [42]. Also, STAT3 can stimulate the
expression of a number of effector genes which in turn sup-
press the expression of pro-inflammatory genes. These in-
clude Bcl3, which impairs NF-κB binding to DNA and sup-
press TNF-α production [20], as well as the suppressors of
cytokine signaling 3 (SOCS3) protein, which blocks the IL-6-
mediated pro-inflammatory response by binding to the IL-6
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receptor [47]. According to Wang [42], prolonged activation
of STAT3 requires repeated phosphorylation which is mediat-
ed by new synthesis and secretion of IL-6. Our results suggest
that HMGB1 contributed to this process through TLR4 sig-
naling. We observed that increased HMGB1 expression and
its interactions with TLR4 were accompanied by increased
phosphorylation of JAK1 and increased nuclear expression
of phosphorylated STAT3 isoforms. The EP-associated de-
crease in HMGB1 expression in diabetic liver accompanied
the decreases in JAK1 phosphorylation and STAT3 activation.
According to Kim et al. [18], the mechanism of inhibition of
STAT3 by EP is the result of JAK2 inhibition. This implies
that EP, which decreased HMGB1 secretion and HMGB1/
TLR4 interactions, reduced JAK1 activation and consequent-
ly STAT3 activation and the expression of STAT3-responsive
inflammatory genes (e.g., IL-6, TNF-α, Hp).
All TLR signaling pathways culminate in the activation of
MAPKs and downstream NF-κB transcription factors. Also,
TNF-α signals via distinct cell surface receptors that activate
all three types of MAPKs and NF-κB p65 [34]. In the present
study, we observed that increased HMGB1/TLR4 interactions
in diabetic liver were accompanied by increased activation of
NF-κB p65 and its accumulation in the nucleus where it con-
trols the expression of an array of inflammatory cytokine
genes (IL-6, TNF-α) whose expression is involved in the
AP reaction. This includes increased Hp production, as well
as the response to oxidative stress and apoptosis induction
[26]. Gene knockout studies suggest that NF-κB p50/p65 het-
erodimers possess anti-inflammatory roles due to direct inhi-
bition of the expression of some pro-inflammatory genes and
the effect on the expression or activity of anti-inflammatory
cytokines [15].We also show that the treatment of diabetic rats
with EP significantly decreased the activation of MAPKs, the
nuclear accumulation of activated NF-κB p65, and induced a
decline in Hp expression in the liver although it remained
significantly higher than in control rats. A possible explana-
tion for this result is that EP induced the translocation of Nrf2
transcription factor to the nucleus where it transactivated the
genes involved in oxidative stress and the inflammatory re-
sponses. According to Thimmulappa et al. [39], Hp gene
could be one of the genes regulated by Nrf2; however, in
what way Nrf2 contributes to Hp expression is still not
fully understood. Zhao et al. [49] demonstrated that after
intracerebral hemorrhage, the levels of Hp in blood plasma
were strongly increased in animals treated with the activa-
tor of Nrf2, sulforaphane.
It is now clear that the ratio of nuclear Nrf2 and NF-κB p65
is an essential element of cellular reactions that determine the
inflammatory response and oxidative status of the cell and
tissue. Nrf2 and NF-κB pathways have been proposed to in-
hibit each other at the transcription level via protein-protein
interactions or through secondary messenger effects [43]. By
inhibiting NF-κB p65-mediated cytokine production, Nrf2
acts as an anti-inflammatory component. In diabetic liver,
we observed a significant decrease in the nuclear presence of
Nrf2 and increased production of IL-6 and TNF-α, which
suggests that excessive HMGB1 release potentiates a decreas-
ing Nrf2/NF-kB p65 ratio, thus attenuating the anti-
inflammatory potential in diabetic liver. Also, this decrease
correlates with attenuation of the antioxidative potential, as
judged by the observed decrease in the activity and expression
of CAT whose gene transcription is primarily regulated by
Nrf2 [24]. We also assume that the decrease in the Nrf2/
NF-κB p65 ratio probably lowered to some extent the efficacy
of HO-1 gene expression, especially because increases in this
ratio in the liver of EP-treated diabetic rats followed increased
expression of HO-1 and CAT. Despite observed decrease in
total SOD activity, the results presented herein show that rel-
ative expression level of CuZnSOD was unchanged in diabet-
ic liver, while the level of MnSOD was increased. The rise
could be interpreted as the result of increased NF-kB p65
expression. Induction of the MnSOD gene transcription in
response to oxidative stress, TNF-α, and IL-6 has been well
established, and studies have identified NF-κB p65 as the
most crucial transcriptional factor regulating MnSOD induc-
tion [29]. CuZnSOD gene is often constitutively expressed
and not as easily inducible as other SOD. In accordance with
this, increased Nrf2/NF-kB p65 ratio in the liver of EP-treated
diabetic rats follows decreased expression of MnSOD. The
disagreement between the detected levels of SOD enzymes
and activity of total SOD could be the consequence of post-
translational modification(s) of CuZn- and MnSOD. Namely,
according to Dinić et al. [9], both SOD enzymes, as well as
CAT, are subjected to O-linked β-N-acetylglucosamine (O-
GlcNAc) modification in the liver of STZ-diabetic rats. By
modulating the local protein structure, O-GlcNAcylation of
these enzymes could influence the effects of phosphorylation,
which has been detected on SOD proteins and/or it could
partially or completely block their catalytic domains and
activity.
The presented data highlight the intricacy of HMGB1 ac-
tion as an inflammatory mediator during diabetes and its com-
plicated influence on the extent of liver damage. The expres-
sion level of exogenous HMGB1 and the functional interac-
tion between HMGB1/TLR4, IL-6, and TNF-α signaling
pathways probably determine the physiological outcome of
HMGB1-generated responses. Despite the described anti-
inflammatory roles of HMGB1 and participants in HMGB1/
TLR4 signaling, inflammation persists in diabetic liver. In the
state with a high presence of exogenous HMGB1, anti-
inflammatory actions are overwhelmed by pro-inflammatory
actions that ultimately prevail as the consequence of continual
HMGB1/TLR4 signaling. Despite this, the prevention of
HMGB1 release or blockade of the HMGB/TLR4 axis should
be effective in ameliorating diabetes-induced inflammation
and slowing down the advance in liver injury.
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